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Abstract
The constant research in therapeutics for mesothelioma has been improving 
their tumor response and overall survival, generating the need to propose markers 
that guide the doctor’s therapeutic approach in a more precise way. Recently, dif-
ferent predictive factors have been proposed, such as mesothelin-related peptides, 
fibulin-3, and osteopontin associated with an image giving information about the 
probability of tumor response to a therapeutic agent or a combination of agents. As 
is well known, the importance of prognostic markers of utility lies in providing pro-
spective information on the evolution of the patient and thus their ability to guide 
therapeutic decisions. Although the clinical stage and histology are currently the 
most described prognostic factors, recent studies have shown interest in the expres-
sion of estrogen receptor beta and calretinin, among other promising factors. Given 
the heterogeneity of this broad field of research in mesothelioma, it is necessary to 
objectively present the prognostic and predictive factors of greater clinical utility.
Keywords: prognosis factors, predictive factors, response to treatment, clinical 
factors, histopathology factors, biological factors, clinical scores
1. Introduction
The prognosis of patients with mesothelioma is unfavorable, with a median 
survival of approximately 12 months from diagnosis [1–5]; this makes a clear need to 
improve the effectiveness of multimodality approaches and to define in a better way 
the subgroups’ prognosis [6–9]. One way to achieve this objective is the use of prognos-
tic and predictive factors; a prognostic factor provides prospective information on the 
evolution of the patient being able to guide therapeutic decisions, while a predictive 
factor gives us information on the probability of tumor response to a therapeutic agent.
The characteristics that a prognostic factor must meet are: (a) simple prediction 
method, (b) wide availability, (c) sensitivity, and (d) reproducibility in any clinical 
situation. The purpose of these markers is to help define the individual prognosis of 
clinical groups, select patients who may need other treatments, and assign the most 
effective treatments to improve survival and quality of life.
Although currently the therapeutic decisions are still based on the classic clinical 
and pathological prognostic factors already known, such as age, functional status, 
sex, chest pain, weight loss, thrombocytosis, leukocytosis, anemia, and histological 




Multiple mesothelioma series have validated advanced TNM stage, age ≥ 50 years, 
male gender, poor performance status, weight loss, platelet counts ≥400,000, 
white blood cell counts ≥15.5, low hemoglobin level, low albumin levels, and high 
serum lactate dehydrogenase levels, among others, as poor predictive and prognosis 
factors [11–21].
TNM stage is one of the most studied prognosis factors describing a poor sur-
vival prognosis for those with advanced or metastatic stage, however, in the same 
stage of the disease, patients’ survival varies widely suggesting that TNM staging is 
not completely precise to predict a survival outcome [16]. Moreover, with the new 
changes applied since the release of the eighth edition of the TNM Classification for 
Lung and Pleural Tumors where all patients N0M0 malignant pleural mesothelioma 
as stage IA or IB, differing from the seventh edition classification, in which N0 also 
was listed within the classifications for stages II and III. These changes reclassi-
fied as stage I many patients who were formerly considered as stage II or III since 
some patients at stage IB experienced poorer prognosis than those at stage III [22, 
23]. Identifying prognostic factors based on the new classification should help to 
identify the patients with a poor prognosis who may benefit from multimodality 
treatments. Additional to the TNM staging system, the true tumor volume was 
independently associated with overall survival and response to treatment; however, 
more studies need to be done to validate this variable [24–27].
Previous studies have suggested that females with mesothelioma experience longer 
survival compared to males [6, 28–33] with possible suggested explications like those 
they present at earlier stage [34], tumors with more favorable histology [30], different 
asbestos exposure responsible for a more indolent tumor biology [35], and a protec-
tive effect of circulating estrogen interacting with estrogen receptors present in their 
tumors, [32, 36, 37] however, only more indolent tumor biology associated to higher 
frequency of germline mutations in DNA repair genes [38–41] and interaction of estro-
gens with estrogen receptor beta [36, 37, 42, 43], other theories still controversial [15].
Platelet count is a practical and easy blood test in clinical practice that has been 
studied for its role as a prognosis factor due to the interaction of platelets with 
tumor cells contributing to tumor progression, invasion, metastasis, and angiogen-
esis.[44]. This interaction could be explained by five possible pathways: the first 
one refers to the release of growth factor by the platelets, including transforming 
growth factor β and fibroblast growth factor enhancing cancer cell proliferation 
[45]. Second, platelet membranes are rich in many adhesin molecules like selectins, 
integrins, immunoglobulin superfamily proteins, and leucine-rich glycoproteins 
stabilizing the cancer cell arrest in the vasculature, increasing potential of metas-
tasis [46]. Third, platelets could mediate the invasive potential of cancer cells by 
the release of thromboxane A2, 12-hydroxyeicosatetranoic acid, and matrix metal-
loproteinases [47–49]. Fourth, platelets release a large number of pro-angiogenic 
mediators such as vascular endothelial growth factor and basic fibroblast growth 
factor influencing the tumor angiogenesis and consequently tumor growth [50–52]. 
Fifth, some studies have demonstrated that platelets facilitate the immune escape 
of cancer cells by surrounding tumor cells and protecting them from the cytotoxic 
effect of natural killer cells [53, 54]. Several studies concluded that thrombocytosis 
is correlated with worse overall survival in patients with mesothelioma, indicating 
that pretreatment could be an adequate and useful factor of prognosis [18].
Recently, many people have focused on the role of inflammation in cancer due to 
its contribution to tumor initiation and malignant progression. More specifically in 
mesothelioma, inflammation becomes relevant since most patients have a history of 
asbestos exposure, and this mineral can skewer cells and set off chemical reactions 
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that lead to inflammation, DNA damage, and cell death [20]. Leukocyte blood count 
reflects a degree of the systemic inflammatory response in tumor patients, being a 
valuable and simple indicator [55]. Blood neutrophil-to-lymphocyte ratio is a systemic 
marker for inflammation closely related to the mortality rate and response to the 
treatment is useful as a predictive and prognostic factor, taking 3 as a dividing point 
[20, 56–60]. In the same way, serum c-protein can reflect an inflammatory environ-
ment; although its usefulness as a prognostic and predictive factor has been demon-
strated in limited studies, more research is needed to validate its utility [61–63].
Malnutrition has been related to adverse outcomes in overall survival, quality 
of life, and increased mortality of malignant tumors [64–66]. Serum albumin level 
is a simple and objective indicator to evaluate malnutrition. Multiple studies have 
demonstrated hypoalbuminemia as an adverse independent prognostic factor for 
mesothelioma [19, 20, 67].
It is well known that cancer cells tend to employ alternate metabolic pathways, 
generating adenosine triphosphate through anaerobic glycolysis regulated by lactate 
dehydrogenase [68, 69]. Several studies assessed the value of high pretreatment lactate 
dehydrogenase levels for the prediction of a worse survival outcome in mesothelioma [10, 
61, 62, 70–75]. The association between high lactate dehydrogenase levels and poor prog-
nosis on malignancies has tried to be explained in multiple ways. The first theory implies 
that the production of lactate acid could be up-regulated by lactate dehydrogenase, 
generating an acidic environment activating metalloproteases, macrophage-mediated 
angiogenesis and protecting mitochondria from oxidative stress, which induces resistance 
to hypoxia-induced apoptosis of tumor cells [76–80]. The second theory explains a strong 
correlation between elevated lactate dehydrogenase levels and an up-regulation of the 
hypoxia-inducible factor pathway resulting in a host immunological function attenua-
tion, and enhanced tumor angiogenesis, which has an adverse impact on prognosis in 
malignant tumors [81]. Despite the great evidence of the utility of lactate dehydrogenase 
as a convenient and cost-effective indicator for predicting overall survival outcome, 
cut-off values of lactate dehydrogenase reported on the literature are inconsistent, and it 
is important to standardize the cut-off value in future studies.
3. Histopathology factors
Together with the TNM stage, the histological type is one of the strongest 
prognostic factors among patients with mesothelioma. However, with the support 
of immunohistochemistry markers, not only has diagnosis been improved, but also 
new markers have appeared for a more accurate prediction of response to treat-
ment, overall survival, and developing better therapeutic approaches.
The most significant prognostic factor until now remains histology with a better 
prognosis for epithelioid type than sarcomatoid or biphasic type mesothelioma 
[10, 12, 82, 83]. In addition to histologic subtyping (with solid growth pattern being 
associated with a poor outcome), nuclear atypia, mitotic count, and the presence of 
necrosis were found to be independent prognostic factors in epithelioid malignant 
pleural mesothelioma [84–86].
Ki67 antigen is used for the assessment of growth fraction of cell populations, 
due to it being exclusively expressed in proliferating cells; cell cycle analysis showed 
that Ki67 is detectable in G1, G2, S, and mitosis phases but absent in quiescent cells 
[87, 88]. Despite most studies indicating that high expression of Ki67 leads to a 
poor prognosis, some malignancies showing high Ki67 levels actually show a better 
response to treatment, which could be explained by the fact that cells with high 
proliferation are susceptible to cytotoxic agents [89–93]. The detection of Ki67 is 
not a routine procedure for mesothelioma’s diagnosis and treatment; however, a 
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group has suggested to consider it due to its utility as a possible prognostic marker 
in epithelioid mesothelioma with a better prognosis outcome in those with low 
expression levels [94–98].
Calretinin is a calcium-binding protein that has been established as a useful marker 
in distinguishing mesothelioma from adenocarcinomas with pleural metastases [99]; 
Additionally, interest in using higher calretinin scores as favorable prognostic factors 
has been growing, although further investigation is needed [100–104].
As mentioned above in the section of clinical factors, estrogen receptor beta 
expressed on mesothelial tumor cells has become a promising prognostic factor and 
a possible future therapeutic target [36, 37, 42, 43].
4. Biological factors
Several biomarkers are selectively elevated in patients with mesothelioma. 
However, further study and validation are required before they are recommended as 
routine predictive or prognosis factors and they should be adjunct to a radiological 
assessment. With considerable variation in response to treatment, the emergence of 
promising biomarkers that could select responders from non-responders at baseline 
or during treatment would guide to a better therapeutic approach, prevent patients 
from getting ineffective treatments, and improve cost-effectiveness.
The most researched biomarker until now is the mesothelin; soluble mesothelin 
is a circulating form of a membrane-bound glycoprotein highly expressed by meso-
thelial cells in mesothelioma (predominantly epithelioid type) and other malignan-
cies [105]. Despite the controversial evidence reported in the literature [106–114], 
a meta-analysis conducted by Tian et al. [115] concluded that a high soluble meso-
thelin level may lead to a poor prognosis for patients with mesothelioma, it being 
appropriate to consider mesothelin level as an independent prognostic marker.
Human fibulin-3 is a secreted glycoprotein that plays an essential role in the 
regulation of cell proliferation and migration [116, 117]. Recent findings have 
documented altered levels on patients with mesothelioma, highlighting them as 
a novel biomarker for this malignancy; however, as most studies have been done 
with limited sample size [114, 118–120], and the results may not completely mirror 
the actual value of fibulin-3 for prognosis, further studies are needed for a more 
comprehensive prognostic role of human fibulin-3 in mesothelioma.
Osteopontin is a glycoprotein that mediates cell-matrix interactions with adverse 
outcomes for mesothelioma [98, 121, 122]; however, its utility is limited because of 
the significant variability in the cut-offs used between studies. In order to be vali-
dated in the future, a consensus approach is required for sampling and analysis [122].
CA 125 is a transmembrane glycoprotein that can be detected in the fallopian 
tube, endometrium, endocervix, and mesothelial surface of the peritoneum, 
pleura, and pericardium [98]. Some cases with non-gynecological cancer showed 
positive immunohistochemical staining for CA125 in tumor tissue and elevated CA 
125 levels in serum [123–125]. The baseline levels of serum CA125 accompanied by 
the stage of the disease could be used as independent prognostic factors for patients 
with mesothelioma; the change in serum CA125 levels can predict overall survival 
and response to systemic treatments [126–128].
5. Clinical scores
The best-known clinical prognostic scoring systems for mesothelioma until 
now derive from the Cancer and Leukemia Group B (CALGB) and the European 
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Organization for Research and Treatment of Cancer (EORTC), both scores have 
been widely used to better select patients who have a favorable prognosis and could 
tolerate and potentially benefit from a more aggressive combined modality treat-
ment [3, 10].
The CALGB index was validated by examining the survival of a wide cohort 
dividing patients into six patient subgroups with different survival rates. The 
CALGB study considered extent pleural disease, lactate dehydrogenase >500 UI/L, 
poor performance status, platelets >400,000, non-epithelial histology, and 
>75 years as negative prognostic factors for survival. The most favorable character-
istics were a performance status of 0, age < 49, and hemoglobin ≥14.6/μl [10].
The EORTC score has been validated in 523 patients included in 10 mesotheli-
oma trials with the analysis suggesting that performance status >0, stage IV disease, 
and biphasic or sarcomatous histologies are associated with a worse outcome [129]. 
Additional reports confirmed that male sex, older age, and abnormal hematological 
values also give a poor prognosis [13, 130].
Despite both studies identifying performance status and histology as two main 
prognostic factors, these analyses included patients with heterogeneous tumor 
stages at diagnosis, the majority of whom underwent major surgery and whose 
treatment predated the use of pemetrexed as first-line treatment. Since the posi-
tioning of pemetrexed as a first-line treatment, no validated prognostic score has 
appeared, resulting in the need to generate new studies with the aforementioned 
scores [131].
6. Promising factors
Although there are multiple prognostic and predictive factors that are currently 
validated, many others have generated great interest for their potential as a therapeutic 
target in the future.
There is an increasing interest in the use of semi-quantitative 18F-FDG PET/
CT parameters, like metabolic tumor volume and total lesion glycolysis to measure 
the metabolic activity in the entire tumor volume with great potential to predict 
response to treatment [119, 132–144]; however further investigation is needed in 
mesothelioma patients.
Despite the wide utility of the tissue biopsy, the invasive nature limits their 
application, especially when repeated biopsies are needed. Given the aforemen-
tioned, liquid biopsy has gained interest from oncologists and basic researchers 
[145]. Although liquid biopsy is still far from replacing tissue biopsy for mesothe-
lioma, plasma and serum samples represent minimally invasive, low-risk, and easily 
obtained biological fluids that many studies have indicated as potentially interesting 
prognosis biomarkers as mentioned in the section “Biological factors” [146].
Nowadays, immunotherapy is gaining great relevance in cancer therapeutics. 
Soon, oncologists will routinely ask for programmed death-ligand 1 (PD-L1) status 
that has been correlated with better treatment response to anti-PD-L1 antibodies 
and overall survival outcomes [147–151]. However, different PD-L1 antibodies 
coupled with specific staining platforms and scoring criteria may be necessary since 
finding a suitable cut-off point remains a current challenge [151, 152].
A wide number of molecular prognostic markers for mesothelioma have been 
investigated. The number of tumor-infiltrating myeloid cells, c-MET expression, 
thymidylate synthase expression, among others, represent promising biomarkers 
associated with strong prognostic significance. c-MET is a tyrosine kinase recep-
tor, its overexpression was associated with longer overall survival in patients with 
mesothelioma [98, 153]. Thymidylate synthase expression may predict pemetrexed 
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efficacy, a certain correlation has also been found with overall survival and 
progression-free survival [154].
Dysregulated genes play a critical role in the development and progression of 
mesothelioma, making them future diagnosis and prognosis biomarkers [155]. 
Recently, Zhou et al. obtained an RNA-Seq count quantified by RSEM for RNA 
expression profiles of a large cohort of patients with mesothelioma according to 
The Cancer Genome Atlas guidelines. After a time-dependent receiver operated a 
characteristic curve to evaluate the prognostic performance of survival prediction, 
three genes (LSM6, GZMB, and HJURP) were found with a strong statistically sig-
nificant prognostic association; this prognostic signature could be a clinically useful 
tool that in the future could be incorporated into a clinical sequencing program to 
individualize therapy [156].
7. Conclusion
Despite the wide variety of predictive and prognostic factors that exist, just a 
few are replicable worldwide. Furthermore, only pathological type and perfor-
mance status are the grade-A recommendations of prognostic factors in pretreat-
ment assessment, as well as the nodal stage, residual disease, and histology during 
treatment [16].
Although there is currently no validated prognostic approach, according to 
individual evidence, availability, and cost-benefit, it is recommended to pay special 
attention to the TNM classification, histological type, and serum CA125 in the 
decision for multimodal therapy. Despite the practicality of the prognostic scoring 
systems, further investigations are needed to validate the known scores or gener-
ated new ones that fit the new existing therapeutic modalities for mesothelioma.
In the near future, many other prognostic and predictive factors may be intro-
duced in clinical practice making a selection of mesothelioma subgroups to improve 
the benefit achievable by currently available treatment strategies, and relentless 
efforts will have to be focused on designing innovative compounds selectively 
targeting the existing (or additional) markers to improve the grim prognosis of the 
disease.
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